Navigation Links
Hana Biosciences Announces Data to be Presented On Talvesta,(Talotrexin) for Injection at The American Association for Cancer,Research Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 11, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, will present preclinical data for Talvesta(tm) (talotrexin) for Injection at the American Association for Cancer Research 100th Annual Meeting April 14-18, 2007 in Los Angeles, California.

Abstract No. 2210: "Combining talotrexin (PT-523) with paclitaxel in A549 non-small cell lung cancer (NSCLC) athymic nude mice xenografts" will be presented in a poster session on Monday, April 16, 2007 from 8:00am to 12:00pm PDT, in Poster Section 23, Tumor Biology 15, in the Exhibit Hall. Board No. 8.

About Talvesta(tm) (talotrexin) for Injection

Talvesta(tm) is a novel nonpolyglutamable antifolate drug under development for the treatment of various types of cancers. Talvesta has demonstrated enhanced antitumor activity in a broad spectrum of preclinical studies by targeting the enzyme DHFR to prevent DNA synthesis in tumor cells and inhibit tumor growth. These studies suggest that Talvesta, as compared to methotrexate, enters into cells up to ten times more efficiently and demonstrates 10- to 100-fold more potency in overcoming polyglutamation, a well-established mechanism of antifolate resistance. Talvesta also binds more tightly to its anti-tumor target DHFR, which Hana believes may further inhibit tumor growth. In May 2006, the U.S. Food and Drug Administration granted orphan drug designation for Talvesta in patients with ALL.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (Nasdaq:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner o
'"/>




Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
2. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
3. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/31/2014)... SAN FRANCISCO , July 31, 2014 /PRNewswire/ ... ) and Aspira Scientific ( Milpitas, California ... joint venture to develop and commercialize new fluorination ... biologically active molecules has benefited from the use ... metabolism, and combine lipophilicity with polarity to improve ...
(Date:7/31/2014)... and LONDON , July 31, 2014 /PRNewswire/ ... services provider for the medical industries, announced today the incorporation of ... United Kingdom has one of the largest ... 8.9 billion in 2012 and it is projected to increase by ... USD 234 billion in 2012, equal to 9.5% of GDP. Despite ...
(Date:7/31/2014)... NEW YORK , July 31, 2014 ... developing better, faster and affordable treatments for tuberculosis (TB), ... Senior Vice President, Market Access. Ms. Robertson joins the ... the company,s business in Sub-Saharan Africa and ... will oversee the TB Alliance,s efforts to ensure beneficial ...
Breaking Medicine Technology:Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2genae Opens Offices in London 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 3
... SAN ANTONIO, July 12, 2011 Sevocity, the ... that Sevocity v11.1 has achieved full certification through ... and is a CCHIT Certified® 2011 Ambulatory EHR. ... usability rating, the highest level awarded by CCHIT. ...
... Surgical Care Affiliates (SCA), a national leader in ... and surgery departments, announced today it has entered into ... subsidiary of Suburban Hospital Healthcare System, Inc., a member ... in the Bethesda and Montgomery County areas. ...
Cached Medicine Technology:Sevocity Division of Conceptual MindWorks Inc.'s Sevocity EHR Earns CCHIT 2011 Certification 2Surgical Care Affiliates Announces Agreement With Suburban Outpatient Surgery Center 2
(Date:7/31/2014)... 31, 2014 The 2013 edition ... about chemical listings, appellate decisions, litigation and settlement ... affect compliance with California's Proposition 65. , The ... law, regulations, history and trends impacting California's Proposition ... installment of the series which adds approximately 200 ...
(Date:7/31/2014)... 2014) Women over the age of 65 face ... obesity, greater struggles against poverty and higher rates of ... the August issue of Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), outlines the ... offers practical solutions to improve their care. ...
(Date:7/31/2014)... used birth control pills containing high-dose estrogen and a ... cancer, whereas women using some other formulations did not, ... a journal of the American Association for Cancer Research. ... contraceptives [birth control pills] in the past year is ... never or former oral contraceptive use, and that this ...
(Date:7/31/2014)... 2014 Developer Jamestown, L.P., has been ... Ponce City Market project in Atlanta’s Old Fourth Ward, ... Company building into best-in-class office, housing, and retail spaces. ... experience with their construction webcam service to assess how ... a construction camera for monitoring and documentation ...
(Date:7/31/2014)... Leelanau Peninsula’s newest winery, Aurora Cellars , opened ... Horn Road in Lake Leelanau. Joining the Northern Loop of ... the 25th winery along the trail. The winery will participate ... making its trail event debut during the Harvest Stompede on ... and Faye Mathia opened the boutique winery in the former ...
Breaking Medicine News(10 mins):Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:Recent use of some birth control pills may increase breast cancer risk 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2
... 28 Dr. Jeffrey Cummings, Medical,Director of The ... the prestigious Ronald and Nancy Reagan Research Award ... themselves to, discovering new,treatments and methods of care ... In his speech of acceptance at the annual ...
... finds molecule boosted cells eliminating colitis, Crohn,s symptoms , , ... by intestinal bacteria can eliminate symptoms of inflammatory bowel ... includes Crohn,s disease and ulcerative colitis. , It ... and other mammals contain about 1,000 different species of ...
... of Pennsylvania School of Medicine have shown how Argos, ... binding growth factors that promote the progression of cancer. ... new drug designs for inhibiting cancer. The study appeared ... Many types of tumors grow because of over-expression of ...
... 300-Page Book, with Foreword by FDA,s Janet Woodcock, ... WASHINGTON, May 28 Now that the Food ... the safe use of,pharmaceuticals, drug manufacturers can be ... their marketing on,existing pharmaceuticals., To help pharmaceutical ...
... DRAXIS Health Inc. ("DRAXIS"),(TSX: DAX) (NASDAQ: DRAX ) ... all of DRAXIS, common shares have been acquired by,an ... common share. As a result, DRAXIS common stock is ... on the Toronto Stock Exchange at,market close on Thursday, ...
... engineer. As a youngster, she had a fascination with ... Today, Sullivan, an assistant professor of chemical engineering at ... applying her knowledge and talents to an area critical ... drugs and gene therapies to diseased and damaged cells ...
Cached Medicine News:Health News:Gut Bacteria Fights Inflammatory Bowel Disease 2Health News:Fruit fly protein acts as decoy to capture tumor growth factors, find Penn researchers 2Health News:FDLI Publishes Comprehensive Handbook on Pharmaceutical Risk Management 2Health News:DRAXIS Announces Completion of Sale to Jubilant 2Health News:DRAXIS Announces Completion of Sale to Jubilant 3Health News:DRAXIS Announces Completion of Sale to Jubilant 4Health News:Sullivan wins NSF Career Award for research on therapeutic drug carriers 2Health News:Sullivan wins NSF Career Award for research on therapeutic drug carriers 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: